Key Summary
Effectiveness of Tirzepatide in Type 2 Diabetes
Tirzepatide, administered at doses of 10 mg or 15 mg once weekly, has not only met its primary goal of noninferiority to semaglutide in the management of type 2 diabetes (T2D) but has also shown superiority over semaglutide in this regard.
Impact on Body Weight and Glycemic Control
Furthermore, tirzepatide is linked to a clinically and statistically significant reduction in body weight when compared to semaglutide. It has achieved glycated hemoglobin (HbA1c) levels approaching normoglycemia, with 51% of patients reaching the target HbA1c.